BioSpace News Archive

Cutera, Inc. (NASDAQ: CUTR) (“Cutera” or the “Company”), a leading provider of energy-based aesthetic systems for practitioners worldwide, today announced that Dave Mowry, Chief Executive Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced Dr. Alex Lugovskoy has joined the Company as Chief Operating Officer, and that the Company has strengthened its Scientific Advisory Board with the addition of leading drug developer and clinician Dr. Rob Hershberg.

Mopec—a leading provider of high-quality pathology, anatomy, mortuary and necropsy equipment and products—is now offering the Guardian Cold Storage Container System, an all-inclusive and temporary solution for morgue capacity issues.

The Government of Canada is taking steps to provide Canadians with effective therapies as part of its response to COVID-19.

Paramit Corporation announced that it has acquired Emphysys, Inc., a leading technology development firm specializing in complex systems and products for the medical device, life sciences, and industrial equipment industries.

Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced today that it has signed an agreement to become a provider in the America’s Choice Provider Network (ACPN).

Adamas Pharmaceuticals, Inc., a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st at 11:45 am Eastern Time.

Urovant Sciences (Nasdaq: UROV) today reported topline data from the Phase 2a randomized, double blind, placebo-controlled clinical trial evaluating once-daily vibegron 75 mg in women with abdominal pain due to irritable bowel syndrome (IBS) with IBS-D (diarrhea) and IBS-M (mixed IBS).

The Board of Directors of BD has declared a quarterly dividend of $0.83 per common share, an increase of 5.1% from the previous quarter.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Evercore’s 3rd Annual HealthCONx virtual conference at 11:20 a.m. ET on Thursday, December 3, 2020.